Having found that FARS2 deficiency could disrupt the MQC system by increasing mitochondrial fission and decreasing fusion, we investigated whether altering mitochondrial dynamics using adeno-associated virus 9 (AAV9) could exert protective effects on cardiac hypertrophy and provide potential clinical benefits (Figure 7A; Figure S17A). The gene discussed is FARS2; the disease is cardiac hypertrophy.